Novo Nordisk launches NovoDose

PRINCETON, N.J. Novo Nordisk has launched a mobile dosing app for healthcare professionals that prescribe the drug maker's insulin products.

NovoDose, which is available for download on iTunes, allows physicians to select the type of insulin they want to research and review suggested guidelines for dosing, titration and even blood glucose goals for their patients. The app also provides important safety information on the products, and only those who self-identify as healthcare professionals can download the app.

NovoDose specifically caters to Novo Nordisk's modern insulin analog portfolio: Levemir (insulin detemir [rDNA origin] injection), NovoLog (insulin aspart [rDNA origin] injection) and NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).

"Physicians are embracing the Internet as part of how they practice medicine — from accessing clinical trials online to networking with peers across the country through sites like SERMO, most physicians agree that access to information online is an asset to their practice," said Camille Lee, VP diabetes marketing for Novo Nordisk. "We're taking that one step further with NovoDose by literally putting that information in the palm of their hands."